Holen Sie sich die Stockscreener-App
33.20
3.20%
1.03
Handel nachbörslich:
33.03
-0.17
-0.51%
Schlusskurs vom Vortag:
$32.17
Offen:
$32.48
24-Stunden-Volumen:
1.91M
Relative Volume:
0.66
Marktkapitalisierung:
$3.84B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-359.64M
KGV:
-10.43
EPS:
-3.1831
Netto-Cashflow:
$-278.69M
1W Leistung:
-1.04%
1M Leistung:
+0.24%
6M Leistung:
+32.32%
1J Leistung:
+18.66%
1-Tages-Spanne:
$32.48
$33.76
1-Wochen-Bereich:
$31.49
$34.50
52-Wochen-Spanne:
$18.92
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Firmenname
Viking Therapeutics Inc
Sektor
Branche
Telefon
858-704-4660
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
33.20 | 3.72B | 0 | -359.64M | -278.69M | -3.1831 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Goldman | Neutral |
| 2025-02-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-07 | Eingeleitet | Citigroup | Neutral |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-22 | Eingeleitet | B. Riley Securities | Buy |
| 2024-11-04 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-11 | Eingeleitet | JP Morgan | Overweight |
| 2024-06-27 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-07 | Eingeleitet | Jefferies | Buy |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2023-05-31 | Fortgesetzt | ROTH MKM | Buy |
| 2023-03-28 | Bestätigt | Maxim Group | Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2021-07-29 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-05-01 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-25 | Eingeleitet | Stifel | Buy |
| 2019-03-29 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Bestätigt | Maxim Group | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-18 | Bestätigt | Maxim Group | Buy |
| 2018-09-18 | Bestätigt | Raymond James | Outperform |
| 2018-07-20 | Eingeleitet | SunTrust | Buy |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-01 | Bestätigt | Laidlaw | Buy |
| 2018-05-31 | Bestätigt | Maxim Group | Buy |
| 2018-03-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | Maxim Group | Buy |
| 2017-11-21 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
Meadowbrook Wealth Management LLC Invests $1.31 Million in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics Secures Manufacturing Might Ahead of Pivotal Data - AD HOC NEWS
Assessing Viking Therapeutics (VKTX) Valuation As Clinical Pipeline Progress Shapes Investor Expectations - simplywall.st
Why Shares of Viking Therapeutics, Inc. (VKTX) Fell More Sharply Than the Overall Market Today - Bitget
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today - Yahoo Finance
Viking Therapeutics: Can Its Obesity Drug Pipeline Justify a Multi-Billion Dollar Valuation? - AD HOC NEWS
Why Viking Therapeutics Stock Could Take Off Later This Year - The Motley Fool
Viking Therapeutics: An Equally Important Catalyst Ahead (NASDAQ:VKTX) - Seeking Alpha
HC Wainwright Reiterates "Buy" Rating for Viking Therapeutics (NASDAQ:VKTX) - MarketBeat
Viking Therapeutics (VKTX) Receives Reiterated "Buy" Rating from HC Wainwright & Co. | VKTX Stock News - GuruFocus
Does Viking Therapeutics (NASDAQ:VKTX) Show Stability In The Nasdaq 100 Index? - Kalkine Media
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics - AOL.com
Got $1,500? Is It Better to Buy Bitcoin, or Viking Therapeutics? - The Motley Fool
Profit Investment Management LLC Sells 58,559 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Trading Systems Reacting to (VKTX) Volatility - Stock Traders Daily
Morgan Stanley Maintains Viking Therapeutics (VKTX) Overweight Recommendation - MSN
Viking Therapeutics, Inc. (VKTX) rises higher than market: Key facts - MSN
Viking Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | 1VKTX | US92686J1060 - marketscreener.com
Viking Therapeutics: Phase 3 Obesity Data Feels Like A Coin Toss (Rating Downgrade) (VKTX) - Seeking Alpha
VIKING THERAPEUTICS, INC. (VKTX) - MSN
BTIG Reiterates a Buy Rating on Viking Therapeutics (VKTX) With a $125 PT - MSN
Viking Therapeutics, Inc. (VKTX) exceeds market returns: Some facts to consider - MSN
Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):